Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Clinical trial NCT05757791 · RECRUITING

Trial details

NCT number: NCT05757791
Sponsor: NYU Langone Health
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Major Depressive Disorder

Start date: 2023-03-17
Primary completion: 2026-04-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.